Loading stock data…
Ocugen (OCGN)
$1.67+0.17 (+11.33%)
After Hours$1.66-0.01 (-0.55%)· Last close Jun 29
Ocugen, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies, biologic, and vaccines that improve patients' health.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Ocugen, Inc. in the Healthcare sector is trading at $1.67 with a market capitalization of $398M. Wall Street consensus targets $11.43 (7 analysts), implying a +584.3% move over the next 12 months. The stock is currently 39% below its 52-week high of $2.73, remaining 8.4% above its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 70/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +584.3% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $1.53M↑ | -$193,000↓ | $1.75M↑ | $1.37M↓ | $1.48M |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$17.84M↓ | -$17.00M↑ | -$17.63M↓ | -$13.79M↑ | -$14.50M |
| Net Income | -$19.18M↓ | -$17.71M↑ | -$20.05M↓ | -$14.74M↑ | -$15.35M |
Peer Comparison
JNJUNHPFE
Fundamentals
Ocugen, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies, biologic, and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene thera...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$397.76M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-1234.68%
Volume
Today's trading volume
14.03M
Recent News
Ocugen (OCGN) Stock Draws Fresh Price Target Split After Cautious Analyst View
Ocugen’s model fair value holds at US$11.43 per share, with no change to the underlying price target despite fresh clinical and financing updates. That stability reflects a cautious analyst stance that reins in more aggressive valuation assumptions while still recognizing the early stage profile of Ocugen’s pipeline. As you read on, you will see how this updated narrative, and the data behind it, can help you track Ocugen’s evolving story. Analyst Price Targets don't always capture the full...
How The Ocugen (OCGN) Investment Story Is Evolving Without New Analyst Guidance
Ocugen’s latest analyst update comes with no change in its price target, leaving existing expectations intact for now. With no new analyst commentary accompanying this update, investors are left to interpret the steady price target in the context of their own view on the stock. In the sections that follow, you will see how to track these kinds of updates so you can keep up with the evolving narrative around Ocugen. Stay updated as the Fair Value for Ocugen shifts by adding it to your...
Why Is Ocugen (OCGN) Down 10.7% Since Last Earnings Report?
Ocugen (OCGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Ocugen's Gene-Agnostic Eye Therapies Could Reshape Late-Stage Care
OCGN is advancing gene-agnostic eye therapies across retinal diseases, with key trial data and regulatory milestones approaching in 2026 and 2027.
Is OCGN Stock Worth the Risk Ahead of 2026-27 Eye Gene Therapy Data?
Ocugen faces cash burn and dilution risks, but upcoming eye gene therapy data and planned filings through 2027 could shape its next phase.